Veracyte, Inc. (VCYT) Forward P/S Multiple

Brandmark of Veracyte (VCYT)

Veracyte, Inc. (VCYT) maintains stable cash flows driven by the integration of its tests into medical standards. However, reliance on Medicare reimbursement rates and R&D expenditures create certain risks. The operating model relies on cloud data processing while maintaining proprietary technologies. The expected price-to-sales ratio on the GURU.Markets base chart reflects valuation dynamics where 3.50 serves as the final level marker.

VCYT Veracyte Inc: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

VCYT (Veracyte Diagnostics): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Veracyte|VCYT - Analyst Median Target
- market capitalization details:
Market Capitalization Veracyte Diagnostics|VCYT - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Veracyte|VCYT - Book Valuation of Business|Market Cap to Net Assets Ratio veracyte.com|VCYT - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Veracyte, Inc.|VCYT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Veracyte, Inc.|VCYT - Aggregate Debt Obligations|Debts to Book Capitalization Veracyte Diagnostics|VCYT - Company Long-Term Debts|Company Short-Term Debts Veracyte|Quick Liquidity Indicator veracyte.com
- business earnings and investment ratios data:
VCYT - Company Net Income|Future Profit Veracyte, Inc.|VCYT - Market Price to Net Income Ratio|Forward P/E Multiple Veracyte Corp|VCYT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Veracyte Diagnostics|VCYT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Veracyte|VCYT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months veracyte.com|VCYT - Earnings per share growth this year|Earnings growth forecast for next year Veracyte, Inc.
- sales volume and revenue indicators:
VCYT - Company Sales|Company Future Sales Volume Veracyte|VCYT - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Veracyte Diagnostics
Summary company analysis:Veracyte VCYT
Product sample of Veracyte, Inc.

The forward P/S ratio relates the current market value of Veracyte, Inc. (VCYT) to projected annual sales, allowing for an assessment of the premium paid for future cash flows. By analyzing this forward price-to-sales chart, an investor can determine whether the expansion of genomic diagnostics and the implementation of cloud analytics in clinics justify the current share price in terms of business scaling.

Competitors of Veracyte, Inc.

Price-to-Projected Revenue Ratio Caris Life Sciences CAI|Market Cap to Expected Sales Ratio Guardant Health Inc (GH)|Celcuity Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRAIL Bio GRAL|Myriad Genetics, Inc. (MYGN) - Price-to-Projected Revenue Ratio|CSTL - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BNR|Price-to-Projected Revenue Ratio VNRX|Forward P/S Multiple BDSX|PRPO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Check-Cap CHEK|Forward Price to Sales MYNZ|OncoCyte - Forward P/S Multiple